首页> 中文期刊> 《中国医药导报》 >雷公藤多苷联合吗替麦考酚酯治疗老年IgA肾病的疗效观察

雷公藤多苷联合吗替麦考酚酯治疗老年IgA肾病的疗效观察

         

摘要

目的 探讨雷公藤多苷联合吗替麦考酚酯(mycophendate mofetil,MMF)治疗老年IgA肾病的安全性和有效性.方法 将我院收治的42例老年IgA肾病患者随机分为两组,观察组22例,予以雷公藤多苷联合MMF进行治疗;对照组20例,单用MMF进行治疗.结果 治疗6个月后,观察组完全缓解率和总有效率均明显高于对照组(P < 0.05);两组患者的尿蛋白排泄量、血清白蛋白、血肌酐、总胆固醇等均得到了明显改善,且观察组明显高于对照组(P < 0.05);观察组和对照组不良反应发生率分别为13.6%与15.0%,两者比较差异无统计学意义(P > 0.05).结论 雷公藤多苷与MMF联合应用,副作用小,可以有效降低蛋白尿.%Objective To explore the safety and efficacy of Tripterygium Wilfordii with Mycophenolate Mofetil (MMF) in the treatment of elderly IgA nephropathy. Methods 42 cases of elderly patients with IgA nephropathy in our hospital were randomly divided into two groups, 22 cases of observation group were given the treatment of Triplerygium Wilfordii with MMF, 20 cases of control group were given MMF alone. Results After treatment for 6 months, complete remission and total effective rate in the observation group were significantly higher than those in control group (P < 0.05); the improvement degree of UPE, serum albumin, Scr, TC in the observation group was significantly higher than thai in control group (P < 0.05); incidence of adverse reactions in observation group and control group were 13.6% and 15.0%, there was no significant difference (P > 0.05). Conclusion Tripterygium Wilfordii with MMF for the treatment of elderly IgA nephropathy is secure and reliable and it is worth of the clinical recommendations.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号